Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;43(Suppl 2):625-633.
doi: 10.1007/s10072-022-06085-w. Epub 2022 May 24.

Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy

Giulia Ricci  1 , Luca Bello  2 , Francesca Torri  1 , Erika Schirinzi  1 , Elena Pegoraro  2 , Gabriele Siciliano  3
Affiliations
Review

Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy

Giulia Ricci et al. Neurol Sci. 2022 Dec.

Abstract

Introduction: Duchenne muscular dystrophy (DMD) is a devastatingly severe genetic muscle disease characterized by childhood-onset muscle weakness, leading to loss of motor function and premature death due to respiratory and cardiac insufficiency.

Discussion: In the following three and half decades, DMD kept its paradigmatic role in the field of muscle diseases, with first systematic description of disease progression with ad hoc outcome measures and the first attempts at correcting the disease-causing gene defect by several molecular targets. Clinical trials are critical for developing and evaluating new treatments for DMD.

Conclusions: In the last 20 years, research efforts converged in characterization of the disease mechanism and development of therapeutic strategies. Same effort needs to be dedicated to the development of outcome measures able to capture clinical benefit in clinical trials.

Keywords: Duchenne muscular dystrophy; Outcome measures; Therapy.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79. doi: 10.1186/s13023-017-0631-3. - DOI - PMC - PubMed
    1. Emery AEH. The muscular dystrophies. Lancet. 2002;359:687–695. doi: 10.1016/S0140-6736(02)07815-7. - DOI - PubMed
    1. Tyler KL. Origins and early descriptions of Duchenne muscular dystrophy? Muscle Nerve. 2003;28:402–422. doi: 10.1002/mus.10435. - DOI - PubMed
    1. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928. doi: 10.1016/0092-8674(87)90579-4. - DOI - PubMed
    1. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509–517. doi: 10.1016/0092-8674(87)90504-6. - DOI - PubMed

LinkOut - more resources